Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders

European Journal of Pain : EJP
Marie-Odile KrebsThérèse M Jay

Abstract

Cannabinoids are proposed in a wide array of medical indications. Yet, the evaluation of adverse effects in controlled clinical studies, following the evidence-based model, has partly been bypassed. On the other hand, studies on the consequences of recreational use of cannabis and experimental studies bring some insights on the potential long-term consequences of cannabinoids use. Epidemiological studies have consistently demonstrated that cannabis use is associated with a risk of persistent cognitive deficits and increased risk of schizophrenia-like psychoses. These risks are modulated by the dose and duration of use, on top of age of use and genetic factors, including partially shared genetic predisposition with schizophrenia. Experimental studies in healthy humans showed that cannabis and its principal psychoactive component, the delta-9-tetrahydrocannabinol (THC), could produce transient, dose-dependent, psychotic symptoms as well as cognitive effects, which can be attenuated by cannabidiol (CBD). Studies in rodents have confirmed these effects and shown that adolescent exposure results in structural changes and impaired synaptic plasticity, impacting fronto-limbic systems that are critically involved in higher brain functi...Continue Reading

References

Aug 16, 2002·American Journal of Epidemiology·J van OsH Verdoux
Nov 26, 2002·BMJ : British Medical Journal·Louise ArseneaultTerrie E Moffitt
Feb 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Louise ArseneaultRobin M Murray
Dec 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Mikkel ArendtPovl Munk-Jørgensen
May 26, 2007·Science·Paul BerghuisTibor Harkany
Sep 23, 2008·Schizophrenia Research·Miguel Ruiz-VeguillaJorge Cervilla
Jun 10, 2010·The International Journal of Neuropsychopharmacology·Céline GoldbergerMarie-Odile Krebs
Nov 12, 2010·Nature·Thomas R Insel
Sep 9, 2011·Psychological Medicine·J H MeijerUNKNOWN Genetic Risk and Outcome of Psychosis (GROUP) Investigators
Aug 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Madeline H MeierTerrie E Moffitt
Oct 9, 2012·Neuron·Pablo E CastilloYuki Hashimotodani
Jan 22, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Bill P GodsilThérèse M Jay
Apr 22, 2014·Current Opinion in Neurobiology·Takako Ohno-Shosaku, Masanobu Kano
Jun 25, 2014·Molecular Psychiatry·R A PowerN G Martin
Nov 27, 2014·Frontiers in Neuroscience·Justine RenardThérèse M Jay
Jan 30, 2015·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Barbara J WeilandKent E Hutchison
Jun 13, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maria MorenaMatthew N Hill
Jun 24, 2015·JAMA : the Journal of the American Medical Association·Deepak Cyril D'Souza, Mohini Ranganathan
Jun 24, 2015·JAMA : the Journal of the American Medical Association·Penny F WhitingJos Kleijnen
Sep 8, 2015·Biological Psychiatry·Tiziana Rubino, Daniela Parolaro
Dec 23, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Justine RenardThérèse M Jay
Jan 17, 2016·Journal of Affective Disorders·Anna-Karin DanielssonYvonne Forsell
Feb 10, 2016·Biological Psychiatry·Valentina LorenzettiMurat Yücel
Feb 10, 2016·Biological Psychiatry·Samantha J BroydNadia Solowij
Feb 18, 2016·Schizophrenia Bulletin·Arianna MarconiEvangelos Vassos
Mar 13, 2016·Biological Psychiatry·Mohamed SherifMohini Ranganathan
Apr 8, 2016·Nature Reviews. Neuroscience·H Valerie CurranLoren H Parsons
Aug 2, 2016·The American Journal of Psychiatry·Ghita DadiMarion Plaze
Jan 25, 2017·Molecular Psychiatry·J VaucherM V Holmes
Mar 6, 2017·The Lancet. Psychiatry·Amir EnglundPhilip McGuire
Jun 22, 2017·Neuropharmacology·R M MurrayD C D'Souza
Jul 26, 2017·Journal of Psychopharmacology·L KoendersJ Cousijn
Aug 31, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deborah S Hasin
Dec 6, 2017·Schizophrenia Bulletin·Steven MarwahaDaniel Smith
Dec 16, 2017·The American Journal of Psychiatry·Philip McGuireStephen Wright
Mar 15, 2018·Neuroscience and Biobehavioral Reviews·Grace Blest-HopleySagnik Bhattacharyya

❮ Previous
Next ❯

Citations

Oct 28, 2019·British Journal of Clinical Pharmacology·Giada CrescioliAlfredo Vannacci
Jun 5, 2019·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Christa E Müller
Jul 18, 2021·Environmental Science and Pollution Research International·Yahya M NaguibZeinab A Kasemy
Dec 12, 2020·Injury Prevention : Journal of the International Society for Child and Adolescent Injury Prevention·Toni Marie Rudisill, Gordon S Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.

Related Papers

Molecular and Cellular Endocrinology
Tiziana Rubino, Daniela Parolaro
Pharmacological Research : the Official Journal of the Italian Pharmacological Society
N RealiniDaniela Parolaro
© 2022 Meta ULC. All rights reserved